Knezevic B, Radevic T, Petronijevic M
Medicina (Kaunas). 2025; 61(2).
PMID: 40005448
PMC: 11857375.
DOI: 10.3390/medicina61020334.
Niu X, Xue F, Ou D, Zheng Y, Hu C, Shen C
Int J Med Sci. 2025; 22(4):933-939.
PMID: 39991768
PMC: 11843132.
DOI: 10.7150/ijms.105995.
Wang M, He L, Yan P
Sci Rep. 2025; 15(1):5645.
PMID: 39955364
PMC: 11830035.
DOI: 10.1038/s41598-025-90211-z.
Lien C, Yeh S, Cheng C, Chiang F, Hwang T, Cai B
Cancers (Basel). 2025; 17(3).
PMID: 39941853
PMC: 11816255.
DOI: 10.3390/cancers17030488.
Guo L, Lu G, Lu Z, Yu Y, Wu S
Infect Agent Cancer. 2025; 20(1):6.
PMID: 39905518
PMC: 11796219.
DOI: 10.1186/s13027-024-00631-1.
Reproduction outcomes and prognostic significance of pregnancy after nasopharyngeal carcinoma treatment.
Luo M, Liu L, Yang Z, Liang Y, Wen D, Liu S
Ann Med. 2025; 57(1):2458196.
PMID: 39898604
PMC: 11792128.
DOI: 10.1080/07853890.2025.2458196.
Retrospective analysis of 1539 nasopharyngeal carcinoma cases: chemotherapy should not be excluded for non-Asian patients with T1-2N1M0 stage.
Li X, Zhong C, Xu H
Front Oncol. 2025; 14:1529136.
PMID: 39896187
PMC: 11782145.
DOI: 10.3389/fonc.2024.1529136.
Epstein-Barr virus-infected nasopharyngeal carcinoma therapeutics: oncoprotein targets and clinical implications.
Mark J, Teh A, Yap B
Med Oncol. 2025; 42(3):59.
PMID: 39888474
DOI: 10.1007/s12032-025-02610-x.
Evaluating the influence of anti-PD-1 immunotherapy combined with IMRT on thyroid dysfunction in nasopharyngeal carcinoma.
Chen L, Li Z, Li X, Wu S, Gong L, Xu G
Front Immunol. 2025; 15:1495946.
PMID: 39885990
PMC: 11779716.
DOI: 10.3389/fimmu.2024.1495946.
Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer - real-world single-centre data.
Patachi B, Jensen K, Gothelf A, Bernsdorf M, Friborg J, Kristensen C
Acta Oncol. 2025; 64:143-146.
PMID: 39876687
PMC: 11794996.
DOI: 10.2340/1651-226X.2025.42128.
A Canadian Perspective on Systemic Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma.
Spreafico A, Winquist E, Ho C, OSullivan B, Bouganim N, Chua N
Curr Oncol. 2025; 32(1).
PMID: 39851964
PMC: 11763457.
DOI: 10.3390/curroncol32010048.
Efficacy of radiotherapy in treating local recurrence concomitant with distant metastasis of nasopharyngeal carcinoma: a long-term retrospective multicenter study.
Li L, Deng M, Ren J, Liao W, Zheng L, Ma H
Clin Exp Metastasis. 2025; 42(2):11.
PMID: 39843651
DOI: 10.1007/s10585-025-10329-2.
Comparison of TPF and PF induction chemotherapy combined with cisplatin concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A systematic review and meta-analysis.
Li H, Wu Q, Luo H, Wu J, Su W, Yu L
Medicine (Baltimore). 2025; 104(3):e41278.
PMID: 39833074
PMC: 11749758.
DOI: 10.1097/MD.0000000000041278.
Unveiling the complex double-edged sword role of exosomes in nasopharyngeal carcinoma.
Huang X, Tang Y
PeerJ. 2025; 13():e18783.
PMID: 39822977
PMC: 11737332.
DOI: 10.7717/peerj.18783.
Combination therapy of low-dose radiotherapy and immunotherapy in advanced metastatic nasopharyngeal carcinoma: a case report and literature review.
Chen C, Huang H, Pan M, Jia Z, Zhang J, Chen Q
Discov Oncol. 2025; 16(1):52.
PMID: 39812951
PMC: 11735707.
DOI: 10.1007/s12672-025-01794-y.
Prediction of Persistent Tumor Status in Nasopharyngeal Carcinoma Post-Radiotherapy-Related Treatment: A Machine Learning Approach.
Tseng H, Shen C, Kao P, Chuang C, Yan D, Liao Y
Cancers (Basel). 2025; 17(1.
PMID: 39796725
PMC: 11720740.
DOI: 10.3390/cancers17010096.
Research Progress of Liquid Biopsy Based on DNA Methylation in Tumor Diagnosis and Treatment.
Bao Y, Wang X, Zeng B, Shi Y, Huang Y, Huang Y
Biomolecules. 2025; 14(12.
PMID: 39766341
PMC: 11727523.
DOI: 10.3390/biom14121634.
An MRI-based radiomics nomogram for preoperative prediction of Ki-67 index in nasopharyngeal carcinoma: a two-center study.
Wang Y, Zhang J, Li Q, Sun L, Zheng Y, Gao C
Front Oncol. 2025; 14:1423304.
PMID: 39759139
PMC: 11695239.
DOI: 10.3389/fonc.2024.1423304.
The multi-target mechanism of action of Selaginella doederleinii Hieron in the treatment of nasopharyngeal carcinoma: a network pharmacology and multi-omics analysis.
Liang H, Fang C, Qiu M
Sci Rep. 2025; 15(1):159.
PMID: 39747499
PMC: 11695685.
DOI: 10.1038/s41598-024-83921-3.
The cellular signaling crosstalk between memory B cells and tumor cells in nasopharyngeal carcinoma cannot be overlooked: Their involvement in tumor progression and treatment strategy is significant.
Li H, Bian Y, Xiahou Z, Zhao Z, Zhao F, Zhang Q
J Cancer. 2025; 16(1):288-314.
PMID: 39744570
PMC: 11660138.
DOI: 10.7150/jca.101420.
